Atlas Trials

Evaluating the Infectivity, Safety, and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants and Children 6 to 24 Months of Age

Clinical trial NCT02952339 · COMPLETED

Trial details

NCT number
NCT02952339
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Respiratory Syncytial Virus Infections
Start date
2016-08-01
Primary completion
2017-07-01
Enrollment
33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.